The COVID-19 pandemic has resulted in significant reductions in cancer screening, cancer management visits, and cancer biopsy procedures across the globe. As a result of lockdowns, cancer screening services were disrupted to some extent, which ultimately lowered the demand for biopsy needles. The repercussions of delayed cancer detection owing to COVID-19 were investigated in a study undertaken in the UK and published in Lancet Oncology in March 2021.
The study covered data from over 100,000 people with breast, colorectal, esophageal, or lung cancer. It found that 1- and 5-year cancer survival rates will be severely reduced because of the outbreak of COVID-19, owing to the reduction in diagnostic biopsies and lack of availability of screening services. However, numerous physician reports from the US have observed a growing number of screening appointments during the last quarter of 2020, which is expected to rise continually.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71036825
COVID-19 led to a significant drop in imaging procedures since March 2020 (for all modalities). A late resurgence of imaging throughput was observed in the second half of 2020; however, the overall throughput remained at a level of roughly 80% of the baseline volume for the entire year.
Globally, there has been a significant increase in the number of people suffering from cancer. This can be attributed to a number of factors, such as lifestyle changes, unhealthy diets, and increasing tobacco consumption. According to estimates from the International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide.
According to the American Cancer Society, about 9.6 million people die from cancer every year, and 70% of cancer deaths occur in low-to-middle income countries such as China and India; these proportions are expected to increase further by 2025. With the rising prevalence of cancer in major regions across the globe, the demand for effective cancer diagnosis is expected to increase in the coming years.
Emerging markets (such as India, China, Brazil, and Mexico) are expected to offer significant growth opportunities for players operating in the aspiration and biopsy needles market. This can be attributed to improvements in the standard of living, presence of a huge target population base (as a result of the rising prevalence of cancer), improvements and expansions in healthcare infrastructure, growing healthcare expenditure, and the modernization of healthcare research facilities in these countries.
The market for aspiration and biopsy needles is primarily driven by the factors such as the rising prevalence of cancer, increasing preference for minimally invasive surgeries, and rise in cancer awareness initiatives undertaken by governments and global health organizations.The Aspiration and Biopsy Needles market is estimated to grow at a CAGR of 7.3% to reach USD 1,272 Million by 2024 from USD 894 Million in 2019.The aspiration and biopsy needles market is segmented into aspiration and biopsy needles.
The biopsy needles segment accounted for the largest share of the aspiration and biopsy needles market in 2018 due to its widespread adoption in healthcare facilities.
This segment is also expected to grow at the highest rate during the forecast period.Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71036825The aspiration and biopsy needles market is segmented into breast, lung, colorectal, prostate, kidney, and bone & bone marrow.
The lung segment is expected to register the highest growth rate due to the increasing prevalence of lung cancer.View complete press release:-https://www.marketsandmarkets.com/PressReleases/aspiration-biopsy-needles.asp
